The treatment of KRAS‐mutant tumors encounters several obstacles, such as acquired drug resistance, tumor immune inertia, and apoptosis tolerance.[1, 35] Hence, exploiting the concept of synthetic lethality is an alternative approach to increasing the vulnerability of cancer cells to oncogenic KRAS activation. The gene discussed is KRAS; the disease is cancer.